Alkem Laboratories
Working at Alkem Laboratories
Company Summary
Overall Rating
10% above
Highly rated for
Salary & Benefits
Critically rated for
Job Security
Work Policy
Top Employees Benefits
About Alkem Laboratories
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. Today, with a footprint in 40 countries, 19 manufacturing units, over 800 brands, and many, many milestones later, we have an assemblage of tales enriched with pioneering work. Alkem is one of the biggest names in the generic and speciality pharmaceutical sector in India. Our legacy is a testament to the sheer hard work, perseverance, and grit to take the path with barely any footprints and a lot of latent potential to make a difference. A single step, a single idea, led to Alkem – a journey driven by our commitment to people, innovation, and service to the community.
Consistently ranked amongst the top ten pharmaceutical companies in India, we embrace the responsibility of making a remarkable impact on people’s lives. Our portfolio includes eminent brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst the top 50 pharmaceutical brands in India.
Alkem Laboratories Ratings
Overall Rating
Category Ratings
Salary & Benefits
Skill Development
Work-Life Balance
Company Culture
Work Satisfaction
Promotions/Appraisal
Job Security
Work Policy at Alkem Laboratories
Alkem Laboratories Reviews
Top mentions in Alkem Laboratories Reviews
Compare Alkem Laboratories with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 3.9/5 based on 2.8k reviews | 4.1/5 based on 5.5k reviews | 4.1/5 based on 6.5k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Salary & Benefits | Salary & Benefits Job Security Skill development | Skill development Salary & Benefits Work-Life balance | Skill development Work-Life balance Salary & Benefits |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 71% employees reported | Work from office 87% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 135 women | 4.1 Good rated by 404 women | 4.1 Good rated by 627 women | - no rating available |
Rating by Men Employees | 3.9 Good rated by 2.4k men | 4.1 Good rated by 4.8k men | 4.1 Good rated by 5.5k men | - no rating available |
Job Security | 3.4 Average | 3.9 Good | 3.7 Good | 4.0 Good |
Alkem Laboratories Salaries
Marketing Executive
Senior Officer
Medical Representative
Area Business Manager
Officer
Research Associate
Regional Sales Manager
Area Sales Manager
Regional Manager
Scientist
Alkem Laboratories Interview Questions
Interview questions by designation
Top interview questions and answers
Interview Process at Alkem Laboratories
People are getting interviews through
Alkem Laboratories Jobs
Alkem Laboratories News
Alkem to transfer trade generics business to subsidiary
- Alkem Laboratories Limited plans to transfer its trade generics business to a subsidiary.
- The transaction involves transferring assets, liabilities, employees, contracts, and other components of the trade generics business.
- The trade generics business contributes approximately ₹1,783.8 crore, representing 18.3% of the company's standalone revenue.
- The move aims to achieve greater business agility, focus on trade generics, and expand market penetration in underserved areas.
Indian Pharma Market Grew 9.9% In November Driven By New Launches, Price Rise
- The Indian pharmaceutical market delivered a growth of 9.9% year-on-year in November 2024 driven by new launches and price rise.
- Except for respiratory and gynaecology, all other top therapies witnessed healthy growth, with derma seeing the highest growth at 15.8%.
- Ind-Ra expects Indian Pharma Market (IPM) growth to be around 8-9% YoY for fiscal 2025, compared to 6.5% YoY in fiscal 2024.
- Leading pharma companies like Alkem Laboratories, Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, and Torrent Pharmaceuticals demonstrated strong performance.
Manish Kumar takes on CHRO role at Paytm Payments Bank
- Manish Kumar has been appointed chief human resources officer (CHRO), Paytm Payments Bank.
- He has moved from UBI Services, where he was chief people officer.
- Kumar has a vast experience in the field of HR, previously serving in various roles at companies like Reliance Capital, Alkem Laboratories, IDFC Bank, and RBS.
- HRKatha wishes Manish Kumar all the best in his new role at Paytm Payments Bank.
Alkem Labs Q2 Results Review - U.S. Drags Earnings: Motilal Oswal
- Alkem Labs Q2 Results Review - U.S. Drags Earnings: Motilal Oswal
- The brokerage maintains a Neutral rating on the stock, given the current valuation captures earnings upside.
- NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies.
- Watch LIVE TV, Get Stock Market Updates, Top Business, IPO and Latest News on NDTV Profit.
Alkem Laboratories Q2 Results: Net Profit Increases 14%, Meets Estimates
- Alkem Laboratories' net profit rose 14% to Rs 702 crore in Q2 2024, meeting estimates.
- The company's Q2 revenue was down 0.7% at Rs 3,415 crore.
- Domestic sales contributed 72.8% of total sales in Q2, reflecting a growth of 5.7%.
- International sales declined by 12.9% in Q2, with the US market contributing 17.7% to total sales.
Q2 Results Live Updates: NBCC, Kalyan Jewellers, Vodafone Idea, Garden Reach To Report Earnings
- Alkem Labs reports a 14% increase in net profit for Q2.
- Prism Johnson records a net loss for Q2, attributed to a one-time gain in Q2 FY24.
- Vodafone Idea is expected to report a net loss of Rs 6,429 crore and revenue of Rs 11,243 crore for Q2.
- NBCC is expected to announce a revenue of Rs 2,533 crore and an Ebitda of Rs 138 crore for Q2.
- Kalyan Jewellers is anticipated to post a net profit of Rs 198 crore and revenue of Rs 5,970 crore for Q2.
MSCI November Rejig: Nuvama Sees Boost In HDFC Bank Weightage, Inclusion Of Adani Energy
- HDFC Bank's weightage is set to increase in MSCI's November reshuffle, attracting an estimated $1.88 billion in inflows.
- Adani Energy Solutions could be included in the MSCI Global Standard Index, along with Kalyan Jewellers, Oberoi Realty, and Alkem Laboratories.
- The official announcement on the adjustments in the MSCI indices is scheduled on November 7, with the rejig taking effect on November 25.
- Nuvama also shared a list of potential inclusions and exclusions in the MSCI Smallcap Index, with small-cap firms expected to draw inflows of around $100 million.
Compare Alkem Laboratories with
Contribute & help others!
Companies Similar to Alkem Laboratories
Alkem Laboratories FAQs
Reviews
Interviews
Salaries
Users/Month